Galés Céline, Poirot Marc, Taillefer Julien, Maigret Bernard, Martinez Jean, Moroder Luis, Escrieut Chantal, Pradayrol Lucien, Fourmy Daniel, Silvente-Poirot Sandrine
Institut National de la Santé et de la Recherche Médicale (INSERM) U 531, Institut Louis Bugnard, CHU Rangueil, Toulouse, France.
Mol Pharmacol. 2003 May;63(5):973-82. doi: 10.1124/mol.63.5.973.
The cholecystokinin (CCK) receptors CCK1R and CCK2R exert important central and peripheral functions by binding the neuropeptide cholecystokinin. Because these receptors are potential therapeutic targets, great interest has been devoted to the identification of efficient ligands that selectively activate or inhibit these receptors. A complete mapping of the CCK binding site in these receptors would help to design new CCK ligands and to optimize their properties. In this view, a molecular model of the CCK2R occupied by CCK was built to identify CCK2R residues that interact with CCK functional groups. No such study has yet been reported for the CCK2R. Docking of CCK in the receptor was performed by taking into account our previous mutagenesis data and by using, as constraint, the direct interaction that we demonstrated between His207 in the CCK2R and Asp8 of CCK (Mol Pharmacol 54:364-371, 1998; J Biol Chem 274:23191-23197, 1999). Two residues that had not been revealed in our previous mutagenesis studies, Tyr189 (Y4.60) and Asn358 (N6.55), were identified in interaction via hydrogen bonds with the C-terminal amide of CCK, a crucial functional group of the peptide. Mutagenesis of Tyr189 (Y4.60) and Asn358 (N6.55) as well as structure-affinity studies with modified CCK analogs validated these interactions and the involvement of both residues in the CCK binding site. These results indicate that the present molecular model is an important tool to identify direct contact points between CCK and the CCK2R and to rapidly progress in mapping of the CCK2R binding site. Moreover, comparison of the present CCK2R.CCK molecular model with that of CCK1R.CCK, which we have previously published and validated, clearly argues that the positioning of CCK in these receptors is different.
胆囊收缩素(CCK)受体CCK1R和CCK2R通过结合神经肽胆囊收缩素发挥重要的中枢和外周功能。由于这些受体是潜在的治疗靶点,人们对鉴定能选择性激活或抑制这些受体的有效配体产生了浓厚兴趣。对这些受体中CCK结合位点进行完整的图谱绘制将有助于设计新的CCK配体并优化其性质。基于此,构建了一个被CCK占据的CCK2R分子模型,以鉴定与CCK官能团相互作用的CCK2R残基。目前尚未有针对CCK2R的此类研究报道。将CCK对接至受体时,考虑了我们之前的诱变数据,并以我们所证明的CCK2R中的His207与CCK的Asp8之间的直接相互作用为约束条件(《分子药理学》54:364 - 371, 1998;《生物化学杂志》274:23191 - 23197, 1999)。在我们之前的诱变研究中未被揭示的两个残基,Tyr189(Y4.60)和Asn358(N6.55),被鉴定出通过氢键与CCK的C末端酰胺相互作用,CCK的C末端酰胺是该肽的一个关键官能团。对Tyr189(Y4.60)和Asn358(N6.55)进行诱变以及用修饰的CCK类似物进行结构 - 亲和力研究验证了这些相互作用以及这两个残基在CCK结合位点中的作用。这些结果表明,当前的分子模型是鉴定CCK与CCK2R之间直接接触点以及在CCK2R结合位点图谱绘制方面快速取得进展的重要工具。此外,将当前的CCK2R.CCK分子模型与我们之前已发表并验证的CCK1R.CCK分子模型进行比较,清楚地表明CCK在这些受体中的定位是不同的。